This is a fillable PDF form; unless you have Adobe Acrobat Professional, you will not be able to save the electronic version of the filled-in form, therefore print the completed form for your files.

National INAD Program

Advanced Sign-up and Information Sheet for 17-α Methyltestosterone Medicated Feed INAD #11-236 for Calendar Year 2011

<u>Note:</u> This is a non-binding preliminary sign-up form to accelerate the preparation of FDA submittals and permanent files at the National INAD Office/AADAP. Final confirmation of this information will be obtained prior to invoicing and submission of enrollment data to FDA.

Company:			
Facility:			
Mailing Address:			
FedEx Address			
Investigator:		e-mail:	
Phone:		Fax:	
Current NPDES Permit Number:			
Monitor:		e-mail:	
Phone:		Fax:	
Mailing Address:			
FedEx Address			
Please list the fish spec appropriate columns	ies strain to be treated	and the maximum number of each species	es to be treated in the
INAD		Fish Species Strain (common/scientific name)	Max. Number Treated
17-α Methyltestosterone Medicated Feed			

The total to be billed to this facility is $$\underline{600.00}$

Please fax, email, or mail completed Sign-up Form by 12/31/10 to:

Ms. Bonnie Johnson

AADAP Office Email: bonnie_johnson@fws.gov

4050 Bridger Canyon Road Ph: (406) 994-9905 Bozeman, MT 59715 Fax: (406) 582-0242

General Information:

- 1. The Investigator and Monitor can not be the same person. Investigators are responsible for conduct of studies and complete and accurate data collection. Study Monitors are responsible for supervision of the trials, adherence of the Investigator to the Study Protocol, and inspection of the site.
- 2. FDA and Rangen, Inc. will be notified of your facility's participation.
- 3. INAD study protocols, forms, and general INAD information can be found on the AADAP website located at http://www.fws.gov/fisheries/aadap/home.htm .
- 4. The AADAP Office has received notification from FDA/CVM that each facility currently participating under INAD #11-236 "...must provide us with written assurance that procedures and/or mitigations are in place to insure 17MT will not be released in effluents or leached to groundwater at concentrations ≥ 1ppb...". Hence, each participating facility will need to send an email or letter to the AADAP Office describing how 17MT effluent from treated tanks is discharged.....and at what level (i.e., less than or equal to 1ppb) 17MT is discharged into public surface waters (please note you may want to attach a diagram of your facility). Please note that written documentation of a MT discharge level as described above will be required for all new INAD participants in 2011 before treatments will be authorized. If you have any questions with this issue, please contact Dave Erdahl at 406-994-9904.